Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

thday. Children born prematurely as well as those with CLD or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract.

About Synagis

Synagis is the only MAb approved by the U.S. Food and Drug Administration (FDA) to help prevent an infectious disease. Since its licensure in 1998, Synagis has been administered to more than 1,000,000 infants in the U.S. and has become the standard of care for infants at high risk for RSV. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease, which is prominent in the Northern Hemisphere during the winter months. Synagis is a humanized MAb given by an intramuscular injection once a month during the RSV season. Synagis was approved in 1998 by the FDA; in 1999, by the European Medicines Evaluation Agency; and in 2002, by the Japanese Ministry of Health, Labor and Welfare. In 2003, the FDA expanded the U.S. label for Synagis for use in young children with hemodynamically significant CHD at risk of RSV disease. To date, Synagis has been approved in 62 countries, including the United States. Synagis is indicated for the prevention of serious lower respiratory t
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:3/2/2015)... 2015 Attorney Advertising -- Bronstein, Gewirtz ... behalf of purchasers of the securities of Vitae ... VTAE -News).  Such investors are advised to contact ... coordinator Eitan Kimelman at info@bgandg.com ... whether Vitae Pharmaceuticals and certain of its officers ...
(Date:3/2/2015)... 2015  CANTEL MEDICAL CORP. (NYSE: CMN ... CEO, will be presenting at the Sidoti & Company ... presentation is scheduled for 2:00 PM ET on Monday, ... New York . In addition, Mr. Krakauer, ... be available for separate one-on-one meetings during the day. ...
(Date:3/2/2015)... 2, 2015  CytomX, a biotechnology company developing ... announced the creation of scientific and clinical advisory ... the fields of cancer immunotherapy and antibody drug ... will provide guidance to CytomX on the development ... and Probody drug conjugates. The company identified advisors ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
(Date:3/2/2015)... 02, 2015 The minimally invasive ... a CAGR of 6.1% to reach $14,133.0 million ... , Factors such as advantages of minimally invasive ... owing to minimally invasive surgeries and increasing number ... driving the global minimally invasive surgical instruments market. ...
(Date:3/2/2015)... Wailea, Maui Hawaii (PRWEB) March 02, 2015 ... Five-Star resort, is celebrating its 25th anniversary this year, having ... commemorate the milestone, the luxury resort is honoring over 70 ... at the resort -- from amongst the approximately 400 original ... dinner on the Resort’s Oceanfront Lawn. , This ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The Alliance ... fire safety expert Mark Chubb to serve as chief ... safety operations and training in Bangladesh and guide remediation ... , “Mark will ensure that the Alliance continues ... safety programs for Bangladesh garment workers,” said Alliance Independent ...
(Date:3/2/2015)... Minneapolis, Minnesota (PRWEB) March 02, 2015 ... a new strategic relationship with First Protective Insurance ... new initiative will allow First Protective affiliated advisors ... and implementation support that Secura Consultants delivers. ... is a national leader in the design and ...
(Date:3/1/2015)... Metamora, Michigan (PRWEB) March 01, 2015 ... approved to treat Overactive Bladder (OAB) symptoms, such as a ... adults when another type of medication (anticholinergic) does not work ... different treatment option that takes another approach to targeting the ... BOTOX® works on the nerves and bladder muscle, blocking the ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2
... BruxZir Solid Zirconia, ... bridge with no porcelain overlay. This new restoration proves strong, reliable and esthetic because of ... ... innovation from Glidewell Dental Lab , is a full-contour solid zirconia crown or bridge ...
... ... thought his story was worth telling. After being diagnosed with Parkinson,s disease ... a manuscript about the experience. Not only could he not find a ... even reading sample chapters. Believing the story needed to be told, Bill ...
... , ... an Atlanta based antivirus company specializing in threat prevention and cloud based antivirus solutions, ... powered mobile devices operate cross carrier and worldwide with Google reporting 60,000 Android handsets ... ...
... ... 32nd Annual National Martial Arts Festival at the Cherry Hill Crowne Plaza Hotel in Cherry Hill, ... (PRWEB) July 1, 2010 -- ... movies, head to Cherry Hill, N.J. The U.S. Soo Bahk Do Moo Duk Kwan Federation, ...
... is already one of medicine,s most successful transplant procedures, ... Now, for the first time, a team of German ... of transplanted corneas are more likely in patients whose ... to surgery. The meta-analysis report appears in July ...
... PA, July 1, 2010 About 1 in 200 women ... 75% of these low-risk, single-baby births planned in advance as ... American Journal of Obstetrics & Gynecology ( AJOG ... results of multiple studies from around the world. They report ...
Cached Medicine News:Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 2Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 3Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 4Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 2Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 3Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 4Health News:Bluepoint Security Launches World's First Cloud Antivirus For The Google Android Mobile Platform 2Health News:700 Karate Kids to Converge on Cherry Hill, NJ July 8-10, 2010 2Health News:Study finds new key to corneal transplant success 2Health News:Planned home births associated with tripling of neonatal mortality rate vs. planned hospital births 2
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
Medicine Products: